We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Kinnate Biopharma Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 56 → 0 (-56)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $92.2M → $0 (-$92.2M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 56

Holders
–
Holders Change
-56
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
56
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
-$25.7M
2
O
OrbiMed
New York
-$21.3M
3
FCMV
Foresite Capital Management V
California
-$9.38M
4
LCM
Lynx1 Capital Management
Puerto Rico
-$5.27M
5
Viking Global Investors
Viking Global Investors
Connecticut
-$4.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management IV
California
– -$25.7M -9,671,643 Closed
O
2
OrbiMed
New York
– -$21.3M -8,009,729 Closed
FCMV
3
Foresite Capital Management V
California
– -$9.38M -3,525,957 Closed
LCM
4
Lynx1 Capital Management
Puerto Rico
– -$5.27M -1,981,106 Closed
Viking Global Investors
5
Viking Global Investors
Connecticut
– -$4.84M -1,820,462 Closed
Vanguard Group
6
Vanguard Group
Pennsylvania
– -$2.86M -1,076,789 Closed
DAM
7
Deltec Asset Management
New York
– -$2.77M -1,039,800 Closed
TCM
8
Tang Capital Management
California
– -$2.6M -977,626 Closed
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
– -$2.56M -964,881 Closed
Renaissance Technologies
10
Renaissance Technologies
New York
– -$2.36M -887,740 Closed
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
– -$1.4M -526,021 Closed
BCM
12
BML Capital Management
Indiana
– -$1.33M -498,851 Closed
YCM
13
Yakira Capital Management
Connecticut
– -$1.32M -496,840 Closed
BlackRock
14
BlackRock
New York
– -$1.15M -431,406 Closed
Group One Trading
15
Group One Trading
Illinois
– -$942K -354,121 Closed
GCP
16
GSA Capital Partners
United Kingdom
– -$890K -334,694 Closed
Millennium Management
17
Millennium Management
New York
– -$711K -267,355 Closed
Geode Capital Management
18
Geode Capital Management
Massachusetts
– -$650K -244,151 Closed
Citadel Advisors
19
Citadel Advisors
Florida
– -$571K -214,664 Closed
Marshall Wace
20
Marshall Wace
United Kingdom
– -$415K -156,089 Closed
TC
21
Trium Capital
United Kingdom
– -$312K -117,456 Closed
Deutsche Bank
22
Deutsche Bank
Germany
– -$305K -114,846 Closed
XT
23
XTX Topco
Cayman Islands
– -$278K -104,437 Closed
EPM
24
Equitec Proprietary Markets
Illinois
– -$274K -103,000 Closed
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
– -$245K -91,961 Closed
1
2 3

KNTE Hedge Fund Activity: Q2 2024 in Review

0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2024, worth a combined $0 — down 100% from $92.2M a quarter earlier.

Sellers outnumbered buyers: 56 funds closed out of KNTE and 0 opened new positions — a net loss of 56 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $25.7M sold.

  • 0 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2024, down from 56 in Q1 2024.
  • Funds reported $0 of Kinnate Biopharma Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2024 and 56 closed out, a net change of -56 holders.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2024 was Foresite Capital Management IV, an estimated $25.7M sold.

Based on aggregated 13F filings for Q2 2024.